Literature DB >> 17561568

Novel extended-spectrum beta-lactamase in Shigella sonnei.

Agnes Lefort, Guillaume Arlet, Olivier F Join-Lambert, Marc Lecuit, Olivier Lortholary.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17561568      PMCID: PMC2725971          DOI: 10.3201/eid1304.061160

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: A 38-year-old French man with a history of chronic juvenile arthritis was referred to the Necker-Enfants Malades University hospital (Paris, France) with a dysenteric syndrome. The patient had returned the day before from a 1-month stay in Port-au-Prince, Haiti, where he spent most of his time in close contact with young children from an orphanage, most of whom had diarrhea. Clinical examination at admission showed fever (39°C), chills, diffuse abdominal pain, bloody diarrhea, and vomiting. The patient received ceftriaxone, which was stopped on day 4 because initial blood and stool cultures were negative for pathogens and clinical signs had completely resolved. Ten days later, he reported the recurrence of diarrhea without fever. A novel stool culture grew Shigella sonnei. An extended-spectrum β-lactamase (ESBL) was detected by double-disk synergy test; the isolate was also resistant to aminoglycosides (except amikacin), tetracycline, and cotrimoxazole. The strain was susceptible to fluoroquinolones and fosfomycin. It also appeared susceptible to azithromycin (MIC 4 μg/mL), although azithromycin MIC for Shigella spp. should be interpreted with caution (). The patient was successfully treated with azithromycin at a dose of 500 mg/d for 5 days. Azithromycin was preferred to fluoroquinolones to avoid the risk for tendinopathy because of the patient’s history of chronic juvenile arthritis and because this antimicrobial agent was shown to be effective in the treatment of shigellosis caused by multidrug-resistant strains (). To identify the molecular basis of this ESBL, a series of PCR primers were used for detection of TEM-, SHV-, or CTX-M–type ESBL (). Only the TEM PCR showed positive results. Sequencing of 2 independent PCR products showed a new allele (www.lahey.org/studies/temtable.asp). Analysis of the deduced amino acid sequence allowed characterization of TEM-137, derived from TEM-1 with 2 substitutions, Arg-16→Ser and Glu-240→Arg. This ESBL (and resistance to aminoglycosides and tetracyclines) was easily transferred to Escherichia coli J53-2 by conjugation. MICs of β-lactams alone or in association with clavulanic acid, were determined by E-test, according to manufacturer’s instructions (AB Biodisk, Solna, Sweden). High-level resistance to ceftazidime (MIC 32 μg/mL) and intermediate resistance to cefotaxime (MIC 8 μg/mL) were observed; the strain remained susceptible to cefepime and imipenem (MIC 0.5 and 0.25 μg/mL, respectively). Clavulanic acid did not restore susceptibility to ceftazidime (MIC 4 μg/mL) but did restore susceptibility to cefotaxime (MIC 0.5 μg/mL). With clavulanic acid, the MIC of cefepime was 0.06 μg/mL. ESBL in S. sonnei is rare worldwide. In Argentina, a CTX-M-2 was found in an isolate of S. sonnei resistant to cefotaxime but not to ceftazidime (). In South Korea, TEM-15, TEM-17, TEM-19, TEM-20, TEM-52, and CTX-M-14 were characterized in S. sonnei (); TEM-52 and CTX-M-14 were also widely distributed, particularly in Salmonella spp. (,). In Turkey, an isolate of S. sonnei producing CTX-M-3 was reported (). In Hong Kong, sequencing of 2 S. sonnei isolates showed the presence of CTX-M-14 and CTX-M-15 (). Finally, in Bangladesh, 2 isolates of S. sonnei with a class A ESBL were reported; they were not characterized at the molecular level, but the resistance phenotypes suggested a CTX-M type (). In our case, little information on antimicrobial drug resistance could be obtained from Haiti because no systematic investigation on resistance in Enterobacteriaceae is performed. Nevertheless, the emergence of TEM-137 (GenBank accession no. AM286274) harbored by this imported S. sonnei isolate clearly demonstrates that ESBL-associated shigellosis has emerged in Haiti and that potentially large and severe shigellosis outbreaks could occur, for which the use of azithromycin could be beneficial, as illustrated in our patient. Because treating shigellosis is becoming problematic, it is essential to focus on prevention measures such as simple rules of personal hygiene that might drastically decrease the risk of transmission.
  10 in total

1.  Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial.

Authors:  W A Khan; C Seas; U Dhar; M A Salam; M L Bennish
Journal:  Ann Intern Med       Date:  1997-05-01       Impact factor: 25.391

2.  Extended-spectrum beta-lactamase-mediated third-generation cephalosporin resistance in Shigella isolates in Bangladesh.

Authors:  Mahbubur Rahman; Shereen Shoma; Harunur Rashid; A K Siddique; G B Nair; D A Sack
Journal:  J Antimicrob Chemother       Date:  2004-08-25       Impact factor: 5.790

3.  Emergence of CTX-M-type beta-lactam resistance in Shigella spp. in Hong Kong.

Authors:  Terence Kin Man Cheung; Yiu Wai Chu; Grand Ka Lok Tsang; Jessie Yin Wa Ngan; Irene Sau Chun Hui; Kai Man Kam
Journal:  Int J Antimicrob Agents       Date:  2005-04       Impact factor: 5.283

4.  Nosocomial outbreak of pediatric gastroenteritis caused by CTX-M-14-type extended-spectrum beta-lactamase-producing strains of Salmonella enterica serovar London.

Authors:  Dongeun Yong; Young Sik Lim; Jong Hwa Yum; Hyukmin Lee; Kyungwon Lee; Eui-Chong Kim; Bok-Kwon Lee; Yunsop Chong
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

5.  Antimicrobial-resistant Shigella sonnei: limited antimicrobial treatment options for children and challenges of interpreting in vitro azithromycin susceptibility.

Authors:  Sanjay K Jain; Amita Gupta; Brian Glanz; James Dick; George K Siberry
Journal:  Pediatr Infect Dis J       Date:  2005-06       Impact factor: 2.129

6.  Occurrence of extended-spectrum beta-lactamases in members of the genus Shigella in the Republic of Korea.

Authors:  Seonghan Kim; Junyoung Kim; Yeonho Kang; Yongkeun Park; Bokkwon Lee
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

7.  CTX-M-3 extended-spectrum beta-lactamase in a Shigella sonnei clinical isolate: first report from Turkey.

Authors:  Ziya Cibali Acikgoz; Zeynep Gulay; Meral Bicmen; Safiye Gocer; Sohret Gamberzade
Journal:  Scand J Infect Dis       Date:  2003

8.  Diversity of TEM-52 extended-spectrum beta-lactamase-producing non-typhoidal Salmonella isolates in Korea.

Authors:  Kyungwon Lee; Dongeun Yong; Jong Hwa Yum; Ho Hoon Kim; Yunsop Chong
Journal:  J Antimicrob Chemother       Date:  2003-08-13       Impact factor: 5.790

9.  Dissemination of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Paris, France.

Authors:  C Eckert; V Gautier; M Saladin-Allard; N Hidri; C Verdet; Z Ould-Hocine; G Barnaud; F Delisle; A Rossier; T Lambert; A Philippon; G Arlet
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  Third-generation cephalosporin resistance in Shigella sonnei, Argentina.

Authors:  M Radice; C Gonzéález; P Power; M C Vidal; G Gutkind
Journal:  Emerg Infect Dis       Date:  2001 May-Jun       Impact factor: 6.883

  10 in total
  1 in total

1.  Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.

Authors:  S Barnoy; K I Jeong; R F Helm; A E Suvarnapunya; R T Ranallo; S Tzipori; M M Venkatesan
Journal:  Vaccine       Date:  2009-11-20       Impact factor: 3.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.